Daré Bioscience, a women’s health company, has announced the receipt of a $750K grant from the Bill & Melinda Gates Foundation. This funding is earmarked for the development of bacteria-based live biotherapeutic products, aiming to enhance the health of women and newborns globally. This recent grant follows a previous award of approximately $585K from the foundation, granted to Daré in November 2022…
NEXT Life Sciences, the creator of the male contraceptive product Plan A, recently announced a successful $2.5 million funding round to advance the launch of its innovative solution into the market. The Family, a high-impact startup accelerator led the round with participation from Transform VC and a combination of angel investors and early-stage venture funds including entrepreneur Brock Pierce, Transform VC, StartupHealth, Pay…
Illumina Ventures Labs, an incubator for early-stage genomics and precision health companies, has officially launched operations in Foster City, California, and Cambridge, United Kingdom. The venture, part of Illumina Ventures, aims to nurture the growth of start-ups in the healthcare sector, particularly those focusing on genomics. Illumina Ventures Labs is finalizing agreements with several startups, providing them access to advanced genomics laboratories…
Daré Bioscience, a biopharma company specializing in women’s health, has announced the development of DARE-LARC1, a drug delivery platform that can administer therapeutic doses over extended periods. This platform is designed to store and precisely deliver medications for months or years through a single device. The technology behind DARE-LARC1, developed initially at the Massachusetts Institute of Technology by Drs. Robert Langer and…
Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer. The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at…
Biotech research company Qvin has announced the FDA clearance of its innovative Q-Pad and A1c Test, marking a significant advancement in women’s health technology. This approval introduces a new method of health monitoring for millions of American women, particularly those living with diabetes, through menstrual blood testing. The Q-Pad offers a less invasive and more accessible alternative to traditional venous blood draws.…
Heranova Lifesciences has announced the completion of a $13.5M seed and seed+ financing round to develop and offer integrated women’s health solutions. The fresh funds will go towards the launch of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis. Institutional investors including Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital…
In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal…
